SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates

SARS-CoV-2 - Dapaglifozine - Therapeutic Candidates


Dapaglifozine, marketed under the name Forxiga®, is an anti-diabetic drug in the glifozin class. It is a SGLT-2 transporter inhibitor that reduces glycated hemoglobin, leads to weight loss and improves blood pressure in patients with type 2 diabetes. Dapaglifozine may be given alone or in combination with insulin, an antihyperglycemic agent, depending on the degree of diabetes.
Since the start of the Covid-19 pandemic, physicians have observed that some patients are at increased risk of developing serious complications that could lead to death. One of the factors that may increase this risk are cardiometabolic diseases such as hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, and heart and kidney failure. Since inhibitors of SGLT-2 transporters have shown strong protective effects on the heart and kidneys in patients with type 2 diabetes, dapaglifozine could protect these vital organ systems in Covid-19.

Search result : 317 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 91
  • Biochemicals 205
  • Inhibitor/Antagonist/Agonist 106
  • Buffers and reagents 6
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
331-11213-3
 5mg 
331-11213-4
 25mg 
331-11213-5
 100mg 
331-11213-2
 EvaluationSample 
293223-5g
 5g 
T10958-100mg
 100mg 
M1937-5mg
 5mg 
T10958-500mg
 500mg 
293223-1g
 1g 
293223-250mg
 250mg 
293223-500mg
 500mg 
M1937-10mg
 10mg 
M1937-50mg
 50mg 
TRC-D193340-100MG
 100mg